Get to Know Acne’s First Triple Threat
Hilary Baldwin, MD, the Medical Director of the Acne Treatment & Research Center in Morristown, NJ, shares why she is so excited about Cabtreo (clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide, Ortho Dermatologics) and how she is planning to use it in her practice.
A Wrinkle in Time: Innovations in Neuromodulation
There’s lots to be excited about in aesthetic neuromodulation including liquid toxins that promise a fast onset of action and long-lasting results, a possible antidote to botulinum toxin, and new precision injection technology. Michael Gold, MD, the founder of Gold Skin Care Center and Tennessee Clinical Research Center in Nashville, provides an update on the […]
Solving Challenging Cases in Dermatology: This Is How I Do It
Valerie D. Callender, MD, the Founder and Medical Director of the Callender Dermatology & Cosmetic Center and Founder and Principal Investigator for Callender Center for Clinical Research in Washington DC, shares her approaches to challenging cases of acne, deep-etched lines, and melasma.
Embracing Combination Therapy in Rosacea
Identify and document every feature of rosacea and treat each accordingly using a combination of therapies. “Don’t try to do a one-hit wonder,” says Birmingham, Ala-based dermatologist Julie C. Harper, MD, the Past President of the American Acne and Rosacea Society.
Achieving Deep Itch Relief With JAK Inhibitors
[the_ad id=”7333″] The speed and depth of itch relief that is possible today with topical and systemic Janus kinase (JAK) inhibitors is “literally unbelievable,” says Matthew Zirwas, MD, a dermatologist in Bexley, Ohio.
New Insights on the Molecular Drivers of IL-23 Blockade in Psoriasis
A high-resolution spatial and transcriptomic atlas of IL-23 blockade in skin provides new insights on treatment response and resistance in psoriasis patients. Psoriasis vulgaris and other chronic inflammatory diseases improve markedly with therapeutic blockade of IL-23 signaling, but the genetic mechanisms underlying clinical responses remain poorly understood. The study, which was led by Enable Medicine […]
News You Can Use: Verrica Receives Permanent J-Code for YCANTH
The Centers for Medicare & Medicaid Services (CMS) has issued a permanent J-Code (J7354) for Verrica’s YCANTH, a molluscum contagiosum treatment. Under the Healthcare Common Procedure Coding System (HCPCS) process, the J-Code for YCANTH will become fully published April 1, 2024. “By securing a permanent J-Code for YCANTH, we have successfully reached a critical milestone in our […]
PsO Far, PsO Good for Can-Fite’s Oral A3 Adenosine Receptor Agonist
Oral piclidenoson continues to show efficacy and safety in psoriasis, according to the first Phase 3 data which appears in the Journal of the European Academy of Dermatology and Venereology. Can-Fite’s piclidenoson is a novel, first-in-class, A3 adenosine receptor agonist (A3AR) small molecule, orally bioavailable drug that has shown efficacy in Phase II and III psoriasis […]
Arcutis’ Roflumilast Foam Continues to Impress in Seb Derm
Roflumilast foam, 0.3% (Zoryve, Arcutis) bests vehicle in the treatment of seborrheic dermatitis, with 80% of individuals achieving Investigator Global Assessment (IGA) success and 51% of individuals reaching complete clearance at Week 8, according to new research published in the February 2024 issue of the Journal of American Academy of Dermatology. Zoryve foam was approved by […]